New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

被引：0
|
作者：
Assi, Rita [1 ]
Temraz, Sally [1 ]
Shamseddine, Ali [1 ]
Mukherji, Deborah [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol Oncol, Beirut, Lebanon
来源：
CURRENT DRUG TARGETS | 2016年 / 17卷 / 03期
关键词：
Prostate cancer; androgen receptor; abiraterone; enzalutamide; LIGAND-INDEPENDENT ACTIVATION; CIRCULATING TUMOR-CELLS; ABIRATERONE ACETATE; ENZALUTAMIDE RESISTANCE; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; SPLICE VARIANTS; TYROSINE PHOSPHORYLATION; INCREASED SURVIVAL; AR COREGULATORS;
D O I：
10.2174/1389450116666150907101044
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre- and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.
引用
收藏
页码：290 / 302
页数：13
相关论文
共 50 条
  • [21] Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer
    Schweizer, M. T.
    Plymate, S. R.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (08) : 903 - 906
  • [22] Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios G.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (06) : 697 - 707
  • [23] Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor
    Lazaro Quintela, Martin
    Leon Mateos, Luis
    Vazquez Estevez, Sergio
    Fernandez Calvo, Ovidio
    Anido Herranz, Urbano
    Afonso Afonso, Francisco Javier
    Santome, Lucia
    Anton Aparicio, Luis
    CANCER TREATMENT REVIEWS, 2015, 41 (03) : 247 - 253
  • [24] Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
    Brand, Lucas J.
    Dehm, Scott M.
    CURRENT DRUG TARGETS, 2013, 14 (04) : 441 - 449
  • [25] Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
    Yuan, X.
    Cai, C.
    Chen, S.
    Chen, S.
    Yu, Z.
    Balk, S. P. p
    ONCOGENE, 2014, 33 (22) : 2815 - 2825
  • [26] New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
    Attard, Gerhardt
    Richards, Juliet
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1649 - 1657
  • [27] Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer
    Guo, Changcheng
    Yeh, Shuyuan
    Niu, Yuanjie
    Li, Gonghui
    Zheng, Junhua
    Li, Lei
    Chang, Chawnshang
    CANCER LETTERS, 2017, 397 : 133 - 143
  • [28] Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
    Narayanan, Ramesh
    ASIAN JOURNAL OF UROLOGY, 2020, 7 (03) : 271 - 283
  • [29] Targeting Continued Androgen Receptor Signaling in Prostate Cancer
    Massard, Christophe
    Fizazi, Karim
    CLINICAL CANCER RESEARCH, 2011, 17 (12) : 3876 - 3883
  • [30] Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer
    Nikolaos Pyrgidis
    Ioannis Vakalopoulos
    Petros Sountoulides
    Hormones, 2021, 20 : 73 - 84
12345